Tag Archives: LPCN

Hot Value Stocks To Watch For 2019

There’s no official IPO date yet, but Snap Inc. stock is already the buzz of Wall Street right now because of its massive $25 billion valuation.

There are estimates Snapchat could be valued at $40 billion by the time of its IPO. That would make it the biggest IPO since Alibaba Group Holding Ltd. (NYSE: BABA). Plus, projections for Snap Inc. stock’s earnings growth are extremely robust.

And strong earnings growth potential can lead to strong investor interest.

Today, we’ll provide you with everything you need to know about Snapchat before the stock hits the market. We’ll also share our exclusive guide to investing in Snapchat.

But first, here’s a brief history of Snapchat and how it’s grown so fast in five years…

The History of Snapchat

The development of Snapchat was driven by concerns that employers were making hiring decisions based on what users had posted on Facebook Inc. (Nasdaq: FB).

Hot Value Stocks To Watch For 2019: Potlatch Corporation(PCH)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Shares of Potlatchdeltic Corp (NASDAQ:PCH) have received an average recommendation of “Hold” from the nine ratings firms that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and three have issued a buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $49.60.

  • [By Joseph Griffin]

    POPCHAIN (CURRENCY:PCH) traded 3.5% lower against the dollar during the one day period ending at 15:00 PM ET on September 24th. Over the last week, POPCHAIN has traded 8.5% lower against the dollar. POPCHAIN has a market capitalization of $4.63 million and $712,856.00 worth of POPCHAIN was traded on exchanges in the last day. One POPCHAIN token can currently be bought for $0.0138 or 0.00000208 BTC on major exchanges including LBank, CoinBene, Bit-Z and Bilaxy.

  • [By Max Byerly]

    Shares of Potlatchdeltic Corp (NASDAQ:PCH) have received an average rating of “Hold” from the ten research firms that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating on the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $50.83.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Potlatchdeltic (PCH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on PotlatchDeltic (PCH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Value Stocks To Watch For 2019: Lipocine Inc.(LPCN)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Lipocine (LPCN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Hot Value Stocks To Watch For 2019: Ultragenyx Pharmaceutical Inc.(RARE)

Advisors’ Opinion:

  • [By Chris Lange]

    Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is expected to report Phase 2 data from all its tumor-induced osteomalacia patients. Shares of Ultragenyx closed Friday at $76.87, in a 52-week range of $41.67 to $86.10 and with a consensus analyst target of $68.74.

  • [By Joseph Griffin]

    BidaskClub upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a buy rating in a report released on Monday.

    A number of other brokerages have also recently weighed in on RARE. JPMorgan Chase restated an overweight rating and issued a $66.00 price objective (down from $68.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. Evercore ISI upgraded shares of Ultragenyx Pharmaceutical from an in-line rating to an outperform rating in a research note on Monday, January 22nd. Stifel Nicolaus restated a buy rating and issued a $74.00 price objective (down from $85.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, February 21st. ValuEngine upgraded shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research note on Wednesday, April 4th. Finally, Wedbush reiterated a positive rating and set a $71.00 target price (up from $64.00) on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, April 18th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have issued a buy rating to the company. Ultragenyx Pharmaceutical presently has a consensus rating of Buy and an average price target of $69.76.

  • [By Motley Fool Transcribers]

    Ultragenyx Pharmaceutical Inc  (NASDAQ:RARE)Q4 2018 Earnings Conference CallFeb. 19, 2019, 5:00 p.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Todd Campbell]

    A Genentech alumnus, Conner was previously vice president of clinical science at Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biotech that has successfully developed therapies for rare and ultrarare diseases. Prior to that, he was senior medical director at BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), another biotech company that’s successfully developed drugs for rare diseases.

  • [By Shane Hupp]

    Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Director Matthew K. Fust sold 6,319 shares of the business’s stock in a transaction that occurred on Wednesday, May 30th. The shares were sold at an average price of $72.00, for a total value of $454,968.00. Following the transaction, the director now owns 8,750 shares of the company’s stock, valued at $630,000. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.